News
Our portfolio companies are making headlines by changing the life of patients. Stay up-to-date on their latest news.
Show articles
- Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON)
- ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris
- ニュートン・バイオキャピタル、株式会社PRISM BioLabに新規投資
- Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases
- ニュートン・バイオキャピタル、エディットフォース株式会社に追加投資
- Newton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology
- Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
- Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers.
- SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
- Newton Biocapital invests in Flemish start-up DeuterOncology
- Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
- Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON)
- Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update
- ACTICOR BIOTECH ANNOUNCES THE SUCCESS OF THE FIRST PHASE OF ITS ACTIMIS STUDY WITH GLENZOCIMAB IN PATIENTS WITH ACUTE ISCHEMIC STROKE
- ジェイファーマ株式会社 総額 17 億 4 千 6 百万円の資金調達完了
- J-Pharma Raises 1,746 million JPY in Funding
- SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 19.0 MILLION IN AN EQUITY PLACEMENT
- Sequana Medical announces first patient enrolled in RED DESERT – REpeated Dose alfapump® DSR study for Treatment of diuretic-resistant heart failure patients
- Sequana Medical appoints leading experts as Heart Failure Scientific Advisors
- Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)
- SEQUANA MEDICAL announces inclusion of alfapump® in German treatment guidelines (DGVS) for complications of liver cirrhosis
- Sequana Medical announces acceptance of late-breaking abstract of DSR therapy for volume overload in heart failure at Heart Failure 2019 Congress
- EditForce raises 870 million JPY
- エディットフォース株式会社 総額 8 億 7 千万円の資金調達完了
- Sequana Medical raises €27.5 million in successful Initial Public Offerin
- Sequana Medical announces the Coverage of the Base Offering of Its Initial Public Offering on Euronext Brussels
- Sequana Medical Launches Its Initial Public Offering on Euronext Brussels
- Sequana Medical receives Breakthrough Device designation from the FDA for its alfapump®
- 株式会社日本政策投資銀行（DBJ）日欧アーリーステージ医薬品のベンチャーキャピタル Newton Biocapital I pricaf privée SAへの出資契約を締結
- DBJ Signs Contract with Newton Biocapital I Pricaf Privee SA, a Japanese-European Venture Capital Fund for Early Stage Pharmaceuticals
- EPICS Therapeutics to Acquire Ogeda former assets, Adding Drug Discovery & Development Capabilities
- UK NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements
- SEQUANA MEDICAL establishes new corporate headquarters in Ghent, Belgium and raises €8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders
- ACTICOR BIOTECH raises € 15.3 M in a Series B financing
- CHROMACURE S.A., a spin-off from the Université libre de Bruxelles (ULB),is launched with €17m committed equity investment to develop enhanced cancer therapies
- SYNERGIA raises €8.1 million in Series A
- ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE
12月, 1st
Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers
Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe and Japan and focused on the treatment and prevention of chronic diseases, has announced its third investment in Japan. Newton invested EUR 1.2 million (JPY 148 million) in Perseus Proteomics Inc. as part of a total round of EUR 8.1 million. With this investment, Perseus Proteomics will continue its research and development of PPMX-T003 - a key growth driver antibody - and other antibodies in the pipeline.
Perseus Proteomics has been developing PPMX-T003 as a therapeutic drug for various blood cancers, including Polycythemia Vera (PV) and acute myeloid leukemia. Since November 2019, Perseus Proteomics has been conducting a Phase I clinical trial investigating the use of PPMX-T003 as a therapeutic drug for the PV indication.
Takuya Yokokawa, President & CEO of Perseus Proteomics commented: “We are determined to contribute to global medical care through cutting edge antibody technology by developing various new antibody drugs in the pipeline for cancers and other diseases.”
Yao Li, Investment Partner at Newton, commented: “As Newton’s third investment in Japan, Perseus demonstrates an innovative antibody technology and development capability through its strong pipelines. Newton’s existing portfolio is nicely complemented and well-balanced by the inclusion of Perseus Proteomics, which we believe has a huge market potential.”
Dr. Guy Heynen, MD, Investment Partner and CMO of Newton, commented: “PPMX-T003 is uniquely positioned to interfere with a cell nutrient critical to cell proliferation in myelodystrophic syndromes, in particular Polycythemia Vera. Newton is pleased to join Perseus Proteomics to support the progress of its pipeline development toward application / administration to patients (in the clinic)."
About Perseus Proteomics
Name: Perseus Proteomics Inc.
Location: 4-7-6 Komaba Meguro-ku, Tokyo, Japan
Representative Director: Takuya Yokokawa, President & CEO
Business Activities: Pharmaceutical Research & Development
Capital: JPY 100 million (as of November 30, 2020)
Establishment: February 2001
Administrative Division Phone: +81-3-5738-1705
Email: info@ppmx.com
Website: https://www.ppmx.co
About PPMX-T003
PPMX-T003 is an antibody developed to prevent iron intake by cells expressing the transferrin receptor. Transferrin receptor is highly expressed in proliferating cells, especially in erythroblasts and cancer cells.
About Newton Biocapital I
Brussels, Belgium; Alain Parthoens, Managing Partner
Newton Biocapital I is a Venture Capital Firm incorporated in Belgium, focused on financing biotech and life science projects in Europe and Japan for the prevention and treatment of chronic diseases. The fund’s approach as lead investor is to support promising start-up projects as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. The leadership team consists of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects. Newton Biocapital’s mission is to generate substantial financial and societal value by providing innovative, breakthrough, and affordable solutions to patients.
More Information
Newton Biocapital I - Japan
Yao Li (Investment Partner)
yao.li@newtonbiocapital.com
Phone: +81 3 5542 1466
Newton Biocapital I - Belgium
Alain Parthoens (IR/Managing Partner/Founder)
alain.parthoens@newtonbiocapital.com
Phone: +32 (0) 2 899 7850